

Appln No.: 10/646,436
Amendment Dated: May 12, 2005
Reply to Office Action of April 20, 2005

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) An RNA molecule having a length of less than 49 bases and having a sequence effective to mediate degradation or block translation of mRNA that is the transcriptional product of a target gene, wherein the target gene ~~is selected from among genes encoding~~ encodes clusterin, IGFBP-5, IGFBP-2, both IGF-BP-2 and 5 simultaneously, MTF, and B-raf.
2. (original) The RNA molecule of claim 1, wherein the molecule has a length of 16 to 29 nucleotides.
3. (original) The RNA molecule of claim 2, wherein the molecule has a length of 18 to 23 nucleotides.
4. (currently amended) The RNA molecule of claim 3, wherein the ~~target gene is clusterin and the~~ RNA molecule consists of sequences selected from among Seq ID Nos 1 to 16, 58, 59, 61, 62, 64, 65, 67 and 68.
- 5-9. (canceled)
10. (currently amended) A pharmaceutical composition comprising an RNA molecule having a length of less than 49 bases and having a sequence effective to mediate degradation or block translation of mRNA that is the transcriptional product of a target gene, wherein the target gene ~~is selected from among genes encoding~~ encodes clusterin, IGFBP-5, IGFBP-2, both IGF-BP-2 and 5 simultaneously, MTF, and B-raf, together with a pharmaceutically acceptable carrier.
11. (original) The pharmaceutical composition of claim 10, wherein the pharmaceutically acceptable carrier is a sterile injectable solution.
12. (original) The pharmaceutical composition of claim 11, wherein the molecule has a length of 16 to 29 nucleotides.
13. (original) The pharmaceutical composition of claim 12, wherein the molecule has a length of 18 to 23 nucleotides.

Appln No.: 10/646,436
Amendment Dated: May 12, 2005
Reply to Office Action of April 20, 2005

14. (currently amended) The pharmaceutical composition of claim 13, wherein the ~~target gene is clusterin and the~~ RNA molecule consists of sequences selected from among Seq ID Nos 1 to 16, 58, 59, 61, 62, 64, 65, 67 and 68.

15-19. (canceled).

20. (withdrawn, currently amended) A method of treating a cancer that expresses a ~~target protein selected from the group consisting of~~ clusterin, IGFBP-5, IGFBP-2, MTF, and B-raf, comprising administering to an individual in need of treatment an RNA molecule having a length of less than 49 bases and having a sequence effective to mediate degradation or block translation of mRNA that is the transcriptional product of a target gene, wherein the target gene encodes ~~is selected from among genes encoding~~ clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and 5 simultaneously, MTF, and B-raf.

21. (withdrawn) The method of claim 20, wherein the RNA molecule has a length of 16 to 29 nucleotides.

22. (withdrawn) The method of claim 21, wherein the RNA molecule has a length of 18 to 23 nucleotides.

23. (withdrawn, currently amended) The method of claim 22, wherein ~~the target gene is clusterin and the~~ RNA molecule consists of sequences selected from among Seq ID Nos 1 to 16, 58, 59, 61, 62, 64, 65, 67 and 68.

24-28. (canceled)

29. (withdrawn) The method of claim 20, wherein the cancer is selected from the group consisting of sarcomas, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma.

30. (canceled)

31. (new) The RNA molecule of claim 1, wherein the RNA molecule comprises a sequence as defined by Seq. ID No. 10.

32. (new, withdrawn) The RNA molecule of claim 1, wherein the RNA molecule comprises a sequence as defined by Seq. ID No. 68.

33. (new) The pharmaceutical composition of claim 10, wherein the RNA molecule comprises a sequence as defined by Seq. ID No. 10.

Appln No.: 10/646,436

Amendment Dated: May 12, 2005

Reply to Office Action of April 20, 2005

34. (new, withdrawn) The pharmaceutical composition of claim 10, wherein the RNA molecule comprises a sequence as defined by Seq. ID No. 68.